Informations générales (source: ClinicalTrials.gov)
Multicenter Prospective Cohort of Tumors With Pole/D1 Mutation
Observational
Federation Francophone de Cancerologie Digestive (Voir sur ClinicalTrials)
octobre 2021
octobre 2025
09 juillet 2024
Primary objective of this study is to identify and describe the clinico-biological and
molecular characteristics of tumors with somatic POLE (Polymerase ɛ)/POLD1 mutation
identified by molecular biology platforms for all stages and primary sites combined
Etablissements
| Les établissements d'Île-de-France ayant mis à jour leurs données Origine et niveau de fiabilité des données | |||||
|---|---|---|---|---|---|
| CHI DE CRETEIL | Delphine COCHEREAU | 19/06/2025 12:59:02 | Contacter | ||
| Les établissements sans correspondance certaine dans le répertoire FINESS dont les données sont issues de ClinicalTrials.gov Origine et niveau de fiabilité des données | |||||
| CHU -hopital Rangeuil - 31059 - Toulouse - France | Rosine GUIMBAUD, PhD MD | Contact (sur clinicalTrials) | |||
Critères
Tous
Inclusion Criteria:
- Any tumor presenting a variant of the exonuclease domain of POLE (exons 9 to 14)
classified as pathogenic by the project working group, including: the 4 hotspots of
mutations described (codons 286 (P286R/H/L), 411 (V411L), 459 (S459F), 424
(L424/V/I), (2).
- Any tumor presenting a variant of the exonuclease domain of PolD1 (exons 8-12),
classified as pathogenic by the project working group, including : C319Y(10).
Diagnosis made from the date of launch of the cohort and in the previous year
-Age ≥ 18 years
- Any tumor presenting a variant of the exonuclease domain of POLE (exons 9 to 14)
classified as pathogenic by the project working group, including: the 4 hotspots of
mutations described (codons 286 (P286R/H/L), 411 (V411L), 459 (S459F), 424
(L424/V/I), (2).
- Any tumor presenting a variant of the exonuclease domain of PolD1 (exons 8-12),
classified as pathogenic by the project working group, including : C319Y(10).
Diagnosis made from the date of launch of the cohort and in the previous year
-Age ≥ 18 years
- Tumor without POLE or POLD1 mutation
- Tumor with POLE mutation identified in research studies retrospective research
- Opposition of the patient to the registration of his data in the cohort